Part I. Disease-Modifying Drugs Targeting A-beta
By Dr. Rudolph Tanzi, Massachusetts General Hospital
Recent developments regarding drugs aimed at treating and preventing Alzheimer’s disease (AD) by targeting the neurotoxic peptide Abeta.
This article, the first in a series of pieces reviewing promising new AD drugs in development, focuses on novel therapies based on the “A-beta Hypothesis of AD”. These drugs are aimed at retarding disease progression by curbing the accumulation of A-beta, and particularly, A-beta42, in the brain.